X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs PANACEA BIOTECH - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. PANACEA BIOTECH FRESENIUS KABI ONCO./
PANACEA BIOTECH
 
P/E (TTM) x 22.1 20.6 107.3% View Chart
P/BV x 3.1 2.8 112.1% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 FRESENIUS KABI ONCO.   PANACEA BIOTECH
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
PANACEA BIOTECH
Mar-14
FRESENIUS KABI ONCO./
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs176149 118.4%   
Low Rs7982 95.4%   
Sales per share (Unadj.) Rs37.784.1 44.8%  
Earnings per share (Unadj.) Rs5.1-18.3 -27.8%  
Cash flow per share (Unadj.) Rs6.7-6.7 -100.4%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.583.7 50.8%  
Shares outstanding (eoy) m158.2361.25 258.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.4 246.0%   
Avg P/E ratio x25.0-6.3 -396.0%  
P/CF ratio (eoy) x18.9-17.2 -109.8%  
Price / Book Value ratio x3.01.4 216.8%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,1357,074 284.6%   
No. of employees `0001.22.8 41.9%   
Total wages/salary Rs m7031,449 48.5%   
Avg. sales/employee Rs Th5,176.21,874.1 276.2%   
Avg. wages/employee Rs Th610.4527.0 115.8%   
Avg. net profit/employee Rs Th699.6-407.7 -171.6%   
INCOME DATA
Net Sales Rs m5,9635,154 115.7%  
Other income Rs m18100 18.0%   
Total revenues Rs m5,9815,254 113.8%   
Gross profit Rs m1,430-766 -186.6%  
Depreciation Rs m258711 36.3%   
Interest Rs m-261,503 -1.7%   
Profit before tax Rs m1,216-2,881 -42.2%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m-681,771 -3.8%   
Tax Rs m34217 2,036.9%   
Profit after tax Rs m806-1,121 -71.9%  
Gross profit margin %24.0-14.9 -161.3%  
Effective tax rate %28.1-0.6 -4,824.3%   
Net profit margin %13.5-21.8 -62.1%  
BALANCE SHEET DATA
Current assets Rs m5,1023,810 133.9%   
Current liabilities Rs m2,3858,365 28.5%   
Net working cap to sales %45.6-88.4 -51.5%  
Current ratio x2.10.5 469.5%  
Inventory Days Days150156 96.4%  
Debtors Days Days11367 168.5%  
Net fixed assets Rs m5,14814,480 35.6%   
Share capital Rs m15861 258.1%   
"Free" reserves Rs m6,556903 725.9%   
Net worth Rs m6,7325,127 131.3%   
Long term debt Rs m9525,832 16.3%   
Total assets Rs m10,38819,433 53.5%  
Interest coverage x-45.8-0.9 4,994.8%   
Debt to equity ratio x0.11.1 12.4%  
Sales to assets ratio x0.60.3 216.5%   
Return on assets %7.52.0 382.2%  
Return on equity %12.0-21.9 -54.7%  
Return on capital %14.63.6 401.6%  
Exports to sales %74.524.5 303.7%   
Imports to sales %24.810.2 243.3%   
Exports (fob) Rs m4,4411,264 351.4%   
Imports (cif) Rs m1,477525 281.5%   
Fx inflow Rs m5,2981,539 344.2%   
Fx outflow Rs m1,772942 188.1%   
Net fx Rs m3,525597 590.3%   
CASH FLOW
From Operations Rs m1,274599 212.6%  
From Investments Rs m-1,204-438 275.0%  
From Financial Activity Rs m-196-303 64.8%  
Net Cashflow Rs m-126-141 89.4%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.6 50.0%  
FIIs % 9.6 1.3 738.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 23.6 38.6%  
Shareholders   42,599 10,259 415.2%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   SUVEN LIFE  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  SUN PHARMA  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Extends Losses; Pharma Stocks Top Losers(Closing)

After opening the day in red share markets in India witnessed negative trading activity throughout the day, and ended well below the dotted line.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

HDFC Prudence Fund Now HDFC Balanced Advantage Fund - Time To Sell?(Outside View)

May 9, 2018

PersonalFN provides detail analysis on HDFC Balanced Advantage Fund (erstwhile HDFC Prudence Fund and HDFC Growth Fund).

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - TORRENT PHARMA COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS